COVID-19 Impact on Global Selective Cox-2 Inhibitors Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Selective Cox-2 Inhibitors Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Meloxicam
  • 1.4.3 Celecoxib
  • 1.4.4 Etoricoxib
  • 1.4.5 Imrecoxib
  • 1.4.6 Etodolac
  • 1.4.7 Parecoxib
  • 1.4.8 Other
• 1.5 Market by Application
  • 1.5.1 Global Selective Cox-2 Inhibitors Market Share by Application: 2020 VS 2026
  • 1.5.2 Rheumatoid Arthritis
  • 1.5.3 Osteoarthritis
  • 1.5.4 Spondylosis Chronica Ankylopoietica
  • 1.5.5 Other
• 1.6 Coronavirus Disease 2019 (Covid-19): Selective Cox-2 Inhibitors Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Selective Cox-2 Inhibitors Industry
    • 1.6.1.1 Selective Cox-2 Inhibitors Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Selective Cox-2 Inhibitors Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Selective Cox-2 Inhibitors Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Selective Cox-2 Inhibitors Market Perspective (2015-2026)
• 2.2 Selective Cox-2 Inhibitors Growth Trends by Regions
  • 2.2.1 Selective Cox-2 Inhibitors Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Selective Cox-2 Inhibitors Historic Market Share by Regions (2015-2020)
  • 2.2.3 Selective Cox-2 Inhibitors Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Selective Cox-2 Inhibitors Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Selective Cox-2 Inhibitors Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Selective Cox-2 Inhibitors Players by Market Size
  • 3.1.1 Global Top Selective Cox-2 Inhibitors Players by Revenue (2015-2020)
  • 3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Selective Cox-2 Inhibitors Market Concentration Ratio
  • 3.2.1 Global Selective Cox-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Selective Cox-2 Inhibitors Revenue in 2019
• 3.3 Selective Cox-2 Inhibitors Key Players Head office and Area Served
• 3.4 Key Players Selective Cox-2 Inhibitors Product Solution and Service
• 3.5 Date of Enter into Selective Cox-2 Inhibitors Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Selective Cox-2 Inhibitors Historic Market Size by Type (2015-2020)
• 4.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2021-2026)

5 Selective Cox-2 Inhibitors Breakdown Data by Application (2015-2026)

• 5.1 Global Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
• 5.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Selective Cox-2 Inhibitors Market Size (2015-2020)
• 6.2 Selective Cox-2 Inhibitors Key Players in North America (2019-2020)
• 6.3 North America Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
• 6.4 North America Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Selective Cox-2 Inhibitors Market Size (2015-2020)
• 7.2 Selective Cox-2 Inhibitors Key Players in Europe (2019-2020)
• 7.3 Europe Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
• 7.4 Europe Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

8 China

• 8.1 China Selective Cox-2 Inhibitors Market Size (2015-2020)
• 8.2 Selective Cox-2 Inhibitors Key Players in China (2019-2020)
• 8.3 China Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
• 8.4 China Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Selective Cox-2 Inhibitors Market Size (2015-2020)
• 9.2 Selective Cox-2 Inhibitors Key Players in Japan (2019-2020)
• 9.3 Japan Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
• 9.4 Japan Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Selective Cox-2 Inhibitors Market Size (2015-2020)
• 10.2 Selective Cox-2 Inhibitors Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
• 10.4 Southeast Asia Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

11 India

• 11.1 India Selective Cox-2 Inhibitors Market Size (2015-2020)
• 11.2 Selective Cox-2 Inhibitors Key Players in India (2019-2020)
• 11.3 India Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
• 11.4 India Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Selective Cox-2 Inhibitors Market Size (2015-2020)
• 12.2 Selective Cox-2 Inhibitors Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
• 12.4 Central & South America Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Boehringer-Ingelheim
  • 13.1.1 Boehringer-Ingelheim Company Details
  • 13.1.2 Boehringer-Ingelheim Business Overview and Its Total Revenue
  • 13.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Introduction
  • 13.1.4 Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2015-2020))
  • 13.1.5 Boehringer-Ingelheim Recent Development
• 13.2 TerSera Therapeutics
  • 13.2.1 TerSera Therapeutics Company Details
  • 13.2.2 TerSera Therapeutics Business Overview and Its Total Revenue
  • 13.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Introduction
  • 13.2.4 TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 13.2.5 TerSera Therapeutics Recent Development
• 13.3 Iroko Pharmaceuticals
  • 13.3.1 Iroko Pharmaceuticals Company Details
  • 13.3.2 Iroko Pharmaceuticals Business Overview and Its Total Revenue
  • 13.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Introduction
  • 13.3.4 Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 13.3.5 Iroko Pharmaceuticals Recent Development
• 13.4 Apotex
  • 13.4.1 Apotex Company Details
  • 13.4.2 Apotex Business Overview and Its Total Revenue
  • 13.4.3 Apotex Selective Cox-2 Inhibitors Introduction
  • 13.4.4 Apotex Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 13.4.5 Apotex Recent Development
• 13.5 Yung Shin Pharmaceutical
  • 13.5.1 Yung Shin Pharmaceutical Company Details
  • 13.5.2 Yung Shin Pharmaceutical Business Overview and Its Total Revenue
  • 13.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Introduction
  • 13.5.4 Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 13.5.5 Yung Shin Pharmaceutical Recent Development
• 13.6 Breckenridge Pharmaceutical
  • 13.6.1 Breckenridge Pharmaceutical Company Details
  • 13.6.2 Breckenridge Pharmaceutical Business Overview and Its Total Revenue
  • 13.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Introduction
  • 13.6.4 Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 13.6.5 Breckenridge Pharmaceutical Recent Development
• 13.7 Meda Pharmaceuticals
  • 13.7.1 Meda Pharmaceuticals Company Details
  • 13.7.2 Meda Pharmaceuticals Business Overview and Its Total Revenue
  • 13.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Introduction
  • 13.7.4 Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 13.7.5 Meda Pharmaceuticals Recent Development
• 13.8 Cipla
  • 13.8.1 Cipla Company Details
  • 13.8.2 Cipla Business Overview and Its Total Revenue
  • 13.8.3 Cipla Selective Cox-2 Inhibitors Introduction
  • 13.8.4 Cipla Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 13.8.5 Cipla Recent Development
• 13.9 Glenmark Pharmaceuticals
  • 13.9.1 Glenmark Pharmaceuticals Company Details
  • 13.9.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
  • 13.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Introduction
  • 13.9.4 Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 13.9.5 Glenmark Pharmaceuticals Recent Development
• 13.10 Teva
  • 13.10.1 Teva Company Details
  • 13.10.2 Teva Business Overview and Its Total Revenue
  • 13.10.3 Teva Selective Cox-2 Inhibitors Introduction
  • 13.10.4 Teva Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 13.10.5 Teva Recent Development
• 13.11 PuraCap Pharmaceutical
  • 10.11.1 PuraCap Pharmaceutical Company Details
  • 10.11.2 PuraCap Pharmaceutical Business Overview and Its Total Revenue
  • 10.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Introduction
  • 10.11.4 PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.11.5 PuraCap Pharmaceutical Recent Development
• 13.12 Almirall Limited
  • 10.12.1 Almirall Limited Company Details
  • 10.12.2 Almirall Limited Business Overview and Its Total Revenue
  • 10.12.3 Almirall Limited Selective Cox-2 Inhibitors Introduction
  • 10.12.4 Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.12.5 Almirall Limited Recent Development
• 13.13 Lupin Pharmaceuticals
  • 10.13.1 Lupin Pharmaceuticals Company Details
  • 10.13.2 Lupin Pharmaceuticals Business Overview and Its Total Revenue
  • 10.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Introduction
  • 10.13.4 Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.13.5 Lupin Pharmaceuticals Recent Development
• 13.14 Aurobindo Pharma
  • 10.14.1 Aurobindo Pharma Company Details
  • 10.14.2 Aurobindo Pharma Business Overview and Its Total Revenue
  • 10.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Introduction
  • 10.14.4 Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.14.5 Aurobindo Pharma Recent Development
• 13.15 Pfizer
  • 10.15.1 Pfizer Company Details
  • 10.15.2 Pfizer Business Overview and Its Total Revenue
  • 10.15.3 Pfizer Selective Cox-2 Inhibitors Introduction
  • 10.15.4 Pfizer Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.15.5 Pfizer Recent Development
• 13.16 Mylan
  • 10.16.1 Mylan Company Details
  • 10.16.2 Mylan Business Overview and Its Total Revenue
  • 10.16.3 Mylan Selective Cox-2 Inhibitors Introduction
  • 10.16.4 Mylan Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.16.5 Mylan Recent Development
• 13.17 Takeda
  • 10.17.1 Takeda Company Details
  • 10.17.2 Takeda Business Overview and Its Total Revenue
  • 10.17.3 Takeda Selective Cox-2 Inhibitors Introduction
  • 10.17.4 Takeda Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.17.5 Takeda Recent Development
• 13.18 Bayer
  • 10.18.1 Bayer Company Details
  • 10.18.2 Bayer Business Overview and Its Total Revenue
  • 10.18.3 Bayer Selective Cox-2 Inhibitors Introduction
  • 10.18.4 Bayer Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.18.5 Bayer Recent Development
• 13.19 Novacap
  • 10.19.1 Novacap Company Details
  • 10.19.2 Novacap Business Overview and Its Total Revenue
  • 10.19.3 Novacap Selective Cox-2 Inhibitors Introduction
  • 10.19.4 Novacap Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.19.5 Novacap Recent Development
• 13.20 Abbott
  • 10.20.1 Abbott Company Details
  • 10.20.2 Abbott Business Overview and Its Total Revenue
  • 10.20.3 Abbott Selective Cox-2 Inhibitors Introduction
  • 10.20.4 Abbott Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.20.5 Abbott Recent Development
• 13.21 Geri-Care
  • 10.21.1 Geri-Care Company Details
  • 10.21.2 Geri-Care Business Overview and Its Total Revenue
  • 10.21.3 Geri-Care Selective Cox-2 Inhibitors Introduction
  • 10.21.4 Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.21.5 Geri-Care Recent Development
• 13.22 Perrigo
  • 10.22.1 Perrigo Company Details
  • 10.22.2 Perrigo Business Overview and Its Total Revenue
  • 10.22.3 Perrigo Selective Cox-2 Inhibitors Introduction
  • 10.22.4 Perrigo Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.22.5 Perrigo Recent Development
• 13.23 Kopran
  • 10.23.1 Kopran Company Details
  • 10.23.2 Kopran Business Overview and Its Total Revenue
  • 10.23.3 Kopran Selective Cox-2 Inhibitors Introduction
  • 10.23.4 Kopran Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.23.5 Kopran Recent Development
• 13.24 Merck
  • 10.24.1 Merck Company Details
  • 10.24.2 Merck Business Overview and Its Total Revenue
  • 10.24.3 Merck Selective Cox-2 Inhibitors Introduction
  • 10.24.4 Merck Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.24.5 Merck Recent Development
• 13.25 Hengrui pharmaceutical
  • 10.25.1 Hengrui pharmaceutical Company Details
  • 10.25.2 Hengrui pharmaceutical Business Overview and Its Total Revenue
  • 10.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Introduction
  • 10.25.4 Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.25.5 Hengrui pharmaceutical Recent Development
• 13.26 Kelun Group
  • 10.26.1 Kelun Group Company Details
  • 10.26.2 Kelun Group Business Overview and Its Total Revenue
  • 10.26.3 Kelun Group Selective Cox-2 Inhibitors Introduction
  • 10.26.4 Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.26.5 Kelun Group Recent Development
• 13.27 Qilu Pharmaceutical
  • 10.27.1 Qilu Pharmaceutical Company Details
  • 10.27.2 Qilu Pharmaceutical Business Overview and Its Total Revenue
  • 10.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Introduction
  • 10.27.4 Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.27.5 Qilu Pharmaceutical Recent Development
• 13.28 Taro Pharmaceuticals
  • 10.28.1 Taro Pharmaceuticals Company Details
  • 10.28.2 Taro Pharmaceuticals Business Overview and Its Total Revenue
  • 10.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Introduction
  • 10.28.4 Taro Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
  • 10.28.5 Taro Pharmaceuticals Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer